These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

274 related articles for article (PubMed ID: 29682098)

  • 1. Testing for
    Sadlecki P; Grzanka D; Grabiec M
    Dis Markers; 2018; 2018():1497879. PubMed ID: 29682098
    [TBL] [Abstract][Full Text] [Related]  

  • 2. KRAS mutation testing in borderline ovarian tumors and low-grade ovarian carcinomas with a rapid, fully integrated molecular diagnostic system.
    Sadlecki P; Antosik P; Grzanka D; Grabiec M; Walentowicz-Sadlecka M
    Tumour Biol; 2017 Oct; 39(10):1010428317733984. PubMed ID: 28992761
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Determination of BRAF V600E (VE1) protein expression and BRAF gene mutation status in codon 600 in borderline and low-grade ovarian cancers.
    Sadlecki P; Walentowicz P; Bodnar M; Marszalek A; Grabiec M; Walentowicz-Sadlecka M
    Tumour Biol; 2017 May; 39(5):1010428317706230. PubMed ID: 28488545
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mutation of NRAS is a rare genetic event in ovarian low-grade serous carcinoma.
    Xing D; Suryo Rahmanto Y; Zeppernick F; Hannibal CG; Kjaer SK; Vang R; Shih IM; Wang TL
    Hum Pathol; 2017 Oct; 68():87-91. PubMed ID: 28873354
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Genomic classification of serous ovarian cancer with adjacent borderline differentiates RAS pathway and TP53-mutant tumors and identifies NRAS as an oncogenic driver.
    Emmanuel C; Chiew YE; George J; Etemadmoghadam D; Anglesio MS; Sharma R; Russell P; Kennedy C; Fereday S; Hung J; Galletta L; Hogg R; Wain GV; Brand A; Balleine R; MacConaill L; Palescandolo E; Hunter SM; Campbell I; Dobrovic A; Wong SQ; Do H; Clarke CL; Harnett PR; Bowtell DD; deFazio A;
    Clin Cancer Res; 2014 Dec; 20(24):6618-30. PubMed ID: 25316818
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Molecular profiling of low grade serous ovarian tumours identifies novel candidate driver genes.
    Hunter SM; Anglesio MS; Ryland GL; Sharma R; Chiew YE; Rowley SM; Doyle MA; Li J; Gilks CB; Moss P; Allan PE; Stephens AN; Huntsman DG; deFazio A; Bowtell DD; ; Gorringe KL; Campbell IG
    Oncotarget; 2015 Nov; 6(35):37663-77. PubMed ID: 26506417
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Intratumoral heterogeneity in a minority of ovarian low-grade serous carcinomas.
    Tone AA; McConechy MK; Yang W; Ding J; Yip S; Kong E; Wong KK; Gershenson DM; Mackay H; Shah S; Gilks B; Tinker AV; Clarke B; McAlpine JN; Huntsman D
    BMC Cancer; 2014 Dec; 14():982. PubMed ID: 25523272
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Molecular diagnosis in type I epithelial ovarian cancer.
    Sadłecki P; Walentowicz-Sadłecka M; Grabiec M
    Ginekol Pol; 2017; 88(12):692-697. PubMed ID: 29303228
    [TBL] [Abstract][Full Text] [Related]  

  • 9. KRAS (but not BRAF) mutations in ovarian serous borderline tumour are associated with recurrent low-grade serous carcinoma.
    Tsang YT; Deavers MT; Sun CC; Kwan SY; Kuo E; Malpica A; Mok SC; Gershenson DM; Wong KK
    J Pathol; 2013 Dec; 231(4):449-56. PubMed ID: 24549645
    [TBL] [Abstract][Full Text] [Related]  

  • 10.
    Etemadmoghadam D; Azar WJ; Lei Y; Moujaber T; Garsed DW; Kennedy CJ; Fereday S; Mitchell C; Chiew YE; Hendley J; Sharma R; Harnett PR; Li J; Christie EL; Patch AM; George J; Au-Yeung G; Mir Arnau G; Holloway TP; Semple T; Pearson JV; Waddell N; Grimmond SM; Köbel M; Rizos H; Lomakin IB; Bowtell DDL; deFazio A;
    Cancer Res; 2017 Aug; 77(16):4268-4278. PubMed ID: 28646021
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinicopathologic and Molecular Features of Paired Cases of Metachronous Ovarian Serous Borderline Tumor and Subsequent Serous Carcinoma.
    Chui MH; Xing D; Zeppernick F; Wang ZQ; Hannibal CG; Frederiksen K; Kjaer SK; Cope L; Kurman RJ; Shih IM; Wang TL; Vang R
    Am J Surg Pathol; 2019 Nov; 43(11):1462-1472. PubMed ID: 31343420
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical performance evaluation of the Idylla NRAS-BRAF mutation test on retrospectively collected formalin-fixed paraffin-embedded colorectal cancer tissue.
    Johnston L; Power M; Sloan P; Long A; Silmon A; Chaffey B; Lisgo AJ; Little L; Vercauteren E; Steiniche T; Meyer T; Simpson J
    J Clin Pathol; 2018 Apr; 71(4):336-343. PubMed ID: 28899979
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinicopathologic, Immunohistochemical, and Molecular Characteristics of Ovarian Serous Carcinoma With Mixed Morphologic Features of High-grade and Low-grade Serous Carcinoma.
    Zarei S; Wang Y; Jenkins SM; Voss JS; Kerr SE; Bell DA
    Am J Surg Pathol; 2020 Mar; 44(3):316-328. PubMed ID: 31876585
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Loss of p16INK4A expression in low-grade ovarian serous carcinomas.
    Schlosshauer PW; Deligdisch L; Penault-Llorca F; Fatemi D; Qiao R; Yao S; Pearl M; Yang Z; Sheng T; Dong J
    Int J Gynecol Pathol; 2011 Jan; 30(1):22-9. PubMed ID: 21131838
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Epithelial ovarian cancer: rationale for changing the one-fits-all standard treatment regimen to subtype-specific treatment.
    Despierre E; Yesilyurt BT; Lambrechts S; Johnson N; Verheijen R; van der Burg M; Casado A; Rustin G; Berns E; Leunen K; Amant F; Moerman P; Lambrechts D; Vergote I;
    Int J Gynecol Cancer; 2014 Mar; 24(3):468-77. PubMed ID: 24557434
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evaluation of MTAP immunohistochemistry loss of expression in ovarian serous borderline tumors as a potential marker for prognosis and progression.
    Nilforoushan N; Moatamed NA
    Ann Diagn Pathol; 2020 Oct; 48():151582. PubMed ID: 32866902
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The DNA methylomes of serous borderline tumors reveal subgroups with malignant- or benign-like profiles.
    Zeller C; Dai W; Curry E; Siddiq A; Walley A; Masrour N; Kitsou-Mylona I; Anderson G; Ghaem-Maghami S; Brown R; El-Bahrawy M
    Am J Pathol; 2013 Mar; 182(3):668-77. PubMed ID: 23357500
    [TBL] [Abstract][Full Text] [Related]  

  • 18. BRAF mutation is rare in advanced-stage low-grade ovarian serous carcinomas.
    Wong KK; Tsang YT; Deavers MT; Mok SC; Zu Z; Sun C; Malpica A; Wolf JK; Lu KH; Gershenson DM
    Am J Pathol; 2010 Oct; 177(4):1611-7. PubMed ID: 20802181
    [TBL] [Abstract][Full Text] [Related]  

  • 19. KRAS and BRAF mutations in ovarian tumors: a comprehensive study of invasive carcinomas, borderline tumors and extraovarian implants.
    Mayr D; Hirschmann A; Löhrs U; Diebold J
    Gynecol Oncol; 2006 Dec; 103(3):883-7. PubMed ID: 16806438
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The anterior gradient homolog 3 (AGR3) gene is associated with differentiation and survival in ovarian cancer.
    King ER; Tung CS; Tsang YT; Zu Z; Lok GT; Deavers MT; Malpica A; Wolf JK; Lu KH; Birrer MJ; Mok SC; Gershenson DM; Wong KK
    Am J Surg Pathol; 2011 Jun; 35(6):904-12. PubMed ID: 21451362
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.